Medical Imaging of Lehigh Valley, P.C. (MILV P.C.) is proud to bring Histotripsy to Pennsylvania and the Lehigh Valley. This revolutionary technology for treating liver cancer will be available in February 2025. Histotripsy will be performed by MILV P.C. Interventional Radiologists under the direction of Drs. Errin Hoffman, Michael Hodavance, and Mitchell Storace.
Histotripsy is a non-invasive, non-ionizing, and non-thermal procedure for treating liver cancer. Using CT and US guidance, hyperfocused ultrasound waves are delivered through the body to the liver lesion. The sound waves mechanically destroy tumor cells while sparing normal tissue. This innovative technology allows physicians to treat liver cancer without surgery, pain, incisions, radiation, or injury to adjacent organs. An added benefit of Histotripsy is the potential for induction of the “Abscopal Effect” or off target treatment. Tumors are liquefied during treatment with resultant release of tumor antigens. This generates an immune response in which the body attacks and destroys tumors located elsewhere in the body.
Histotripsy is currently FDA approved for the treatment of liver cancer. FDA approval for the treatment of kidney cancer is expected in early 2025. Future indications for Histotripsy include pancreatic cancer, benign prostatic hypertrophy (BPH), breast, and thyroid cancer.
Histotripsy is currently available at only the nation’s top institutions. MILV is excited to bring Histotripsy to the Lehigh Valley providing our patients with the highest level of medical care. MILV P.C. will be the first in Pennsylvania to offer this cutting edge technology.
If you think you may be a candidate for Histotripsy, please contact Medical Imaging of Lehigh Valley P.C. (MILV P.C.) Interventional Radiology at 1255 South Cedar Crest Blvd in Allentown, PA. Please call 888-402-5846.